Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant IP Floxuridine + Chemoradiation for Resected Gastric Cancer
NCT00858338Phase 2Completed
- Sponsor
- NYU Langone Health
- Start
- Dec 2002
- Primary completion
- Mar 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of floxuridine in gastric adenocarcinoma, sponsored by NYU Langone Health. Primary endpoint: Toxicity of IP FUDR at 6 months. Started Dec 2002; status: completed.
02
Drugs
floxuridine
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on NCT00858338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00858338.